284 related articles for article (PubMed ID: 25905984)
1. Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts.
Cheungpasitporn W; Chebib FT; Cornell LD; Brodin ML; Nasr SH; Schinstock CA; Stegall MD; Amer H
Transplantation; 2015 Nov; 99(11):2382-6. PubMed ID: 25905984
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
[TBL] [Abstract][Full Text] [Related]
3. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
Zhang PL; Raza S; Li W; Kanaan HD
Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
[TBL] [Abstract][Full Text] [Related]
4. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
5. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors.
Pellé G; Shweke N; Duong Van Huyen JP; Tricot L; Hessaïne S; Frémeaux-Bacchi V; Hiesse C; Delahousse M
Am J Kidney Dis; 2011 May; 57(5):756-9. PubMed ID: 21295897
[TBL] [Abstract][Full Text] [Related]
6. Incidence of retinal artery occlusion following intravitreal antivascular endothelial growth factor injections.
Gao X; Borkar D; Obeid A; Hsu J; Ho AC; Garg SJ
Acta Ophthalmol; 2019 Sep; 97(6):e938-e939. PubMed ID: 30810272
[No Abstract] [Full Text] [Related]
7. Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: A case report and review of the literature.
Gan G; Michel M; Max A; Sujet-Perone N; Zevering Y; Vermion JC; Zaidi M; Savenkoff B; Perone JM
Br J Clin Pharmacol; 2023 Jan; 89(1):401-409. PubMed ID: 36208427
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
[TBL] [Abstract][Full Text] [Related]
9. [Systemic safety following intravitreal injections of anti-VEGF].
Baillif S; Levy B; Girmens JF; Dumas S; Tadayoni R
J Fr Ophtalmol; 2018 Mar; 41(3):271-276. PubMed ID: 29567019
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
[TBL] [Abstract][Full Text] [Related]
11. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T
JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105
[TBL] [Abstract][Full Text] [Related]
12. Twelve-month outcomes of intra-vitreal anti-VEGF agents for treatment-naïve neovascular age-related macular degeneration eyes: French data from the fight for retinal blindness!
Lestable L; Gabrielle PH; Bron AM; Nguyen P; Creuzot-Garcher C
J Fr Ophtalmol; 2020 Oct; 43(8):761-769. PubMed ID: 32622633
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic Features that Predict Transplant Glomerulopathy Progression in a Chinese Cohort.
Li X; Chen J; Cheng D; Wang W; Xie K; Zhang M; Xu F; Wen J; Tang Z
Am J Nephrol; 2019; 49(6):425-434. PubMed ID: 30991390
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
[TBL] [Abstract][Full Text] [Related]
16. Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.
Von Visger J; Cassol C; Nori U; Franco-Ahumada G; Nadasdy T; Satoskar AA
BMC Nephrol; 2019 Feb; 20(1):53. PubMed ID: 30764798
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
18. Renal transplant patients with preformed anti-HLA antibodies: early biopsy findings and clinical outcomes.
Sousa MV; Zollner RL; Mazzali M
J Bras Nefrol; 2019 Sep; 42(2):201-210. PubMed ID: 31528982
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury.
Touzani F; Geers C; Pozdzik A
Case Rep Nephrol; 2019; 2019():2919080. PubMed ID: 31934470
[TBL] [Abstract][Full Text] [Related]
20. Acute renal failure after intravitreal antivascular endothelial growth factor therapy.
Huang YF; Chen SJ; Hsu MY; Hwang DK
J Formos Med Assoc; 2017 Jun; 116(6):490-492. PubMed ID: 27816404
[No Abstract] [Full Text] [Related]
[Next] [New Search]